Xultophy 100/3.6 market seen growing on rising diabetes demand
A new analysis from The Business Research Company says the global Xultophy 100/3.6 market is set for rapid growth as type 2 diabetes cases rise and demand grows for simpler combination therapies. North America held the largest share in 2025, while the report flags aging populations and higher healthcare spending as additional tailwinds.
Why it matters: - Xultophy 100/3.6 is positioned as a dual-action treatment for type 2 diabetes, a market shaped by rising disease prevalence and pressure to simplify care. - Growth in this segment could reflect broader demand for once-daily, fixed-ratio injectable therapies that may improve adherence and glycemic control.
What happened: - The Business Research Company said the global Xultophy 100/3.6 market is gaining traction and is expected to expand rapidly. - The analysis points to type 2 diabetes growth, wider insulin use, and stronger acceptance of combination injectable treatments as key historical drivers. - The report also identifies North America as the largest regional market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa as additional regions. - A free sample of the market report is available here.
The details: - Xultophy 100/3.6 contains insulin degludec at 100 units per milliliter and liraglutide at 3.6 milligrams per milliliter. - The treatment is designed to manage type 2 diabetes with diet and exercise. - The therapy is a once-daily injection that targets both insulin deficiency and GLP-1 receptor activity. - The market’s future growth is linked to rising adoption of combination therapies, demand for simplified diabetes management, and more focus on weight-neutral glycemic control. - The analysis also cites investment in metabolic disorders and next-generation injectable combinations as growth factors. - Key trends include fixed-ratio combination therapies, once-daily injection regimens, optimized glycemic control, GLP-1-based combination products, and stronger attention to patient adherence. - The report says Xultophy 100/3.6 can reduce the number of injections needed and may lower hypoglycemia and weight-gain risk. - The report says the product is intended to improve blood sugar management by combining insulin degludec and liraglutide in one formulation. - In May 2024, CDC data showed more than 38 million Americans had diabetes, and about 90% to 95% of those cases were type 2 diabetes. - The report says the elderly population is another demand driver because older adults often need convenient treatment options with fewer injections. - In July 2024, the UK Parliament’s House of Commons Library reported that 12.7 million people in the UK were age 65 or older in 2022, equal to 19% of the population. - The same source projected that number to rise to 22.1 million by 2072, or 27% of the population. - Rising healthcare expenditure is also cited as a market support factor because higher spending can improve access to innovative therapies and support research. - In May 2024, the UK Office for National Statistics said total healthcare expenditure rose 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth in 2022. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated trend analysis. - The report also provides expanded strategic intelligence and updated graphics and tables. - The release includes contact information for Saumya Sahay at The Business Research Company and lists company social channels.
Between the lines: - The market case is not just about diabetes prevalence; it is also about convenience, adherence, and broader demand for therapies that combine multiple mechanisms in one shot. - North America’s lead suggests the market is benefiting from established treatment access and diagnosis rates, while other regions may grow at different speeds based on healthcare infrastructure and adoption.
What's next: - The report expects continued expansion as combination injectable therapies gain share and more metabolic disorder investment flows into product development. - Future market performance will likely depend on how quickly patients, providers, and payers adopt simplified diabetes regimens. - The company says regional growth will vary with local diabetes prevalence and treatment uptake.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
One World Daily Brief
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.